Clinical and Experimental Dermatology最新文献

{"title":"Localized Demodicosis of the Scalp Following Hair Transplantation.","authors":"Pelin Koҫyiğit, Feride Ongun, Gizem Öztürk, Özlem Dicle, Aylin Heper","doi":"10.1093/ced/llaf421","DOIUrl":"https://doi.org/10.1093/ced/llaf421","url":null,"abstract":"","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145091123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Assessment of Disease Characteristics and Clinical Outcomes in Alopecia Areata in a Global Noninterventional Observational Cohort (ADAAGIO).","authors":"Keith L Davis, Andrew Messenger, Sergio Vañó-Galván, Helen Tran, Lynne Napatalung, Kent A Hanson, Lizzi Esterberg, Ernest H Law","doi":"10.1093/ced/llaf319","DOIUrl":"https://doi.org/10.1093/ced/llaf319","url":null,"abstract":"<p><strong>Background and objective: </strong>Limited evidence exists on prevailing treatments, disease characteristics, and real-world outcomes of patients with alopecia areata (AA), particularly for those with ≥50% scalp hair loss (SHL). This study sought to address this evidence gap.</p><p><strong>Methods: </strong>This was a retrospective chart review study in the United Kingdom, France, Spain, and Germany. Adults and adolescents with ≥50% SHL were included. First clinical observation of ≥50% SHL defined the study index (2015-2019). Patients had ≥6 months of follow-up from index. Analyses were descriptive. The primary endpoint was absolute Severity of Alopecia Tool (SALT) score, assessed longitudinally. Sustained SALT≤20, assessed via Kaplan-Meier, evaluated time to achieving SALT≤20 without regression to SALT>30 within 6 months.</p><p><strong>Results: </strong>In total, 741 patients were included (median age at index: 27 years; 52.6% female). Mean (SD) SALT score at index was 63.5 (15.6); 80.2% had patchy AA and 19.8% had alopecia totalis or universalis. Topical corticosteroids were the most common treatment post-index, with 55.6% receiving ≥1 course with median cumulative exposure of 4 months. Systemic and intralesional corticosteroids (44.1% and 22.5%, respectively), systemic immunosuppressants (22.0%), and oral (17.3%) or topical (19.4%) minoxidil were also common. Mean (SD) absolute SALT reduction at 12 months post-index was -44.6% (37.3%). However, at 12 months, few patients (10.6%) achieved SALT≤20 that was sustained for ≥6 months.</p><p><strong>Conclusions: </strong>Although patients in this study experienced substantial absolute SALT score reductions, few achieved and sustained SALT≤20. These findings highlight potential suboptimal effectiveness of the varied treatments applied in this population.</p>","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145091134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Topical steroid withdrawal: a patient's story.","authors":"Eliza Wioland, Georgina M Cameron, Susannah M C George","doi":"10.1093/ced/llaf417","DOIUrl":"https://doi.org/10.1093/ced/llaf417","url":null,"abstract":"","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145091170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TYK-ed Off By Rosacea - An Australian Case Series of Rosacea Associated with Deucravacitinib.","authors":"Zachary Warren, Chloe West, Christina Sander, Francis Lai","doi":"10.1093/ced/llaf418","DOIUrl":"https://doi.org/10.1093/ced/llaf418","url":null,"abstract":"<p><p>Deucravacitinib is a novel, oral selective Tyrosine kinase 2 (TYK2) inhibitor used to treat plaque psoriasis. The most common cutaneous adverse effects are acne and folliculitis. However, this report presents seven cases of prototypical papulopustular rosacea (PPR) following the commencement of deucravacitinib. Although most of our patients demonstrated improvement in psoriasis on deucravacitinib, all seven patients discontinued therapy due to the severity and impact of their PPR. Rosacea as an adverse effect of deucravacitinib can be severe, impact on tolerability and influence future treatment options.</p>","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145091137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful treatment of Hailey-Hailey disease with oral roflumilast.","authors":"Giovanni Genovese, Carlo Alberto Maronese, Davide Termini, Luisa Sarno, Stefano Buffon, Federica Derlino, Francesca Laura Boggio, Angelo Valerio Marzano","doi":"10.1093/ced/llaf422","DOIUrl":"https://doi.org/10.1093/ced/llaf422","url":null,"abstract":"","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145091164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Schnitzler Syndrome without Monoclonal Gammopathy: A systematic review and case presentation.","authors":"Catherine Zhu, Elvis Martinez-Jaramillo, Moshe Ben Shoshan, Elena Netchiporouk, May Chergui, Michael Fein","doi":"10.1093/ced/llaf403","DOIUrl":"https://doi.org/10.1093/ced/llaf403","url":null,"abstract":"<p><strong>Background: </strong>Schnitzler syndrome (SS) is a rare autoinflammatory disorder that presents with chronic urticarial rash, neutrophilic urticarial dermatosis, monoclonal IgG or IgM gammopathy, recurrent fever, joint and/or bone pain and enlarged lymph nodes, spleen, and/or liver. Several cases in the literature have described incomplete variants of SS that lack monoclonal gammopathy. This systematic review aims to analyze the current literature regarding the features of Schnitzler-like Syndrome (SLS) and their treatment outcomes; we also report our own case of SLS.</p><p><strong>Methods: </strong>A systematic search of MEDLINE, Embase, Scopus and PubMed was performed (PROSPERO: CRD42024548245). All articles in English or French were included, and no publication date restrictions were applied. All articles with original data, clinical features and treatment outcomes were included. Two reviewers independently conducted screenings and conflicts were resolved by a third reviewer if necessary.</p><p><strong>Results: </strong>15 studies (13 case reports and 2 case series) met inclusion criteria, in addition to one case from our own experience, yielding a total of 18 patients. The majority of our population was male (55.6%) with a median age at diagnosis of 57.5 (IQR=44.8, 62.8). The majority of our patients had absent monoclonal gammopathy (n = 14; 77.8%), and four (22.2%) had delayed-onset monoclonal gammopathy. Antihistamines were the most common treatment (n=17; 94.4%), followed by anakinra (n=14; 77.8%), prednisone (n = 9; 50.0%), unspecified systemic corticosteroids (n=8; 44.4%), omalizumab (n=8; 44.4%), colchicine (n = 5; 27.8%), dapsone (n = 6; 33.3%), cyclosporine (n = 4; 22.2%), canakinumab (n=4; 22.2%), hydroxychloroquine (n=2; 11.1%) and thalidomide (n=1; 5.6%). Of the 14 patients treated with anakinra, 92.9% (n = 13/14) achieved a complete response (CR).</p><p><strong>Conclusions: </strong>Our findings raise the hypothesis that monoclonal gammopathy may not be an obligate criterion for Schnitzler syndrome. We propose this as a consideration for future consensus discussions, emphasizing the potential benefits of early recognition and timely IL-1 inhibitor therapy to improve patient outcomes.</p>","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145091150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment with Rituximab is associated with significantly improved cutaneous sclerosis: real-world observations in an Indian cohort.","authors":"Sanjeev Handa, Anubha Dev, Anuradha Bishnoi, Dipankar De, Rahul Mahajan","doi":"10.1093/ced/llaf420","DOIUrl":"https://doi.org/10.1093/ced/llaf420","url":null,"abstract":"<p><strong>Background: </strong>Rituximab, is effective in both SSc-associated ILD and cutaneous sclerosis. However, most studies report improvement in skin sclerosis as secondary outcomes, leaving a gap in literature on rituximab's dermatological impact. Hence this study evaluates rituximab's effectiveness in reducing skin sclerosis.</p><p><strong>Materials and methods: </strong>This retrospective study was conducted at a tertiary care center in northern India. Records of SSc patients from 2016 to 2023 were reviewed. Clinical assessments, investigations and standard treatment for end organ damage was done according to clinical presentation and EULAR guidelines. Rituximab was administered at a dose of 1g 2 weeks apart to patients having a baseline mRSS of 14 or higher, with or without ILD or a baseline mRSS of greater than seven1 and less than 14 in the presence of ILD, by a departmental protocol. Patients were divided into two groups: those receiving rituximab (rituximab group) and rituximab-naïve patients. Treatment response was evaluated based on change in mRSS and overall survival.</p><p><strong>Results: </strong>Among 98 SSc patients, 37 received rituximab, and 61 were rituximab - naïve. The rituximab group had higher percentage of DSS patients (70.3% vs 29.5%) and higher baseline mRSS (20.1 vs. 11.5). There was significantly greater percentage reduction in mRSS (47.9% vs. 31.2%, p=0.013) in the Rituximab group as compared to the Rituximab naïve group. Overall survival was 65.8% at 140 months in the rituximab group as compared to 53.2% at 95 months in rituximab-naïve group (p=0.851). Patients with LSS had a better survival (77.8% at 100 months) as compared to those with DSS (46.9% at 140 months, p=0.048). On multivariate analysis, a greater percentage reduction in mRSS was the strongest predictor of survival (p=0.039).</p><p><strong>Conclusion: </strong>Rituximab shows significant reduction in skin sclerosis even in patients with more severe baseline skin sclerosis, though it did not demonstrate any survival benefit.</p>","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145091148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinico-demographic characteristics of pemphigus foliaceus: Retrospective analysis of clinic-based data of 103 patients in a non-endemic location.","authors":"Dipankar De, Apoorva Sharma, Vinod Hanumanthu, Debajyoti Chatterjee, Uma Nahar Saikia, Biman Saikia, Rahul Mahajan, Sanjeev Handa","doi":"10.1093/ced/llaf408","DOIUrl":"https://doi.org/10.1093/ced/llaf408","url":null,"abstract":"<p><strong>Background: </strong>Pemphigus foliaceus (PF) is an uncommon autoimmune blistering disease characterized by superficial blistering and erosions of the skin. Literature on PF globally is limited. Understanding the clinicodemographic heterogeneity in PF is crucial for offering improved outcomes for affected individuals.</p><p><strong>Objective: </strong>To study the clinico-demographic characteristics and treatment outcomes of PF patients in north India.</p><p><strong>Methods: </strong>A retrospective study of patients with PF registered to our clinic between November 2013 and June 2023 at a tertiary care centre in north India was conducted.</p><p><strong>Results: </strong>A total of 103 patients with PF were included in the study. The mean age at disease onset was 40.4± 15.7 years, with a male-to-female ratio of 1.7:1. The median duration of the disease at presentation was 18 months (ranging from 1 to 240 months). The most commonly prescribed treatment was topical corticosteroids (n=98, 95.1%) or oral corticosteroids (n=97, 94.1%), either alone or in combination with steroid-sparing adjuvants. Rituximab was the commonest adjuvant used in 45 patients (43.6%). Overall, 78 (75.7%) patients achieved clinical remission on minimal therapy (CRmin) in 6.5 ± 3.9 months and clinical remission off therapy (CRoff) was achieved in 10.4 ± 6.0 months in 69 (66.9%) patients. Among patients in the rituximab group, CRmin was achieved in 41 patients (91.1%) in 6.3 ± 4.6 months and CRoff was achieved in 37 cases (82.2%) in 9 ± 5.6 months.</p><p><strong>Limitations: </strong>The study design is retrospective. Anti-desmoglein antibody titres in the serum were not routinely assessed.</p><p><strong>Conclusion: </strong>PF in the present study was more common in middle-aged males. Corticosteroids (topical/systemic) formed the mainstay of therapy, with rituximab being the most commonly used steroid-sparing adjuvant. Prospective studies in a larger cohort are required in the future for better understanding of this disease in non-endemic locations.</p>","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145032870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"When diagnostic clues are hidden in small blood vessels of the skin: Diagnostic challenge in Intravascular Large B-Cell Lymphoma.","authors":"I-Lun Tseng, Julia Yu-Yun Lee, Chih-Cheng Hsieh, Yu-Chen Chen, Chaw-Ning Lee, Yu-An Wang, Yi-Chen Liao","doi":"10.1093/ced/llaf413","DOIUrl":"https://doi.org/10.1093/ced/llaf413","url":null,"abstract":"<p><p>Intravascular large B-cell lymphoma (IVLBCL) is a rare extranodal lymphoma characterized by selective growth of neoplastic lymphocytes within small vessels, and often lacking lymphadenopathy or circulating malignant cells. Its clinical heterogeneity and nonspecific symptoms frequently cause delayed diagnosis and treatment. We report 3 new cases in elderly patients presenting with unexplained anemia, systemic symptoms in 2 patients, and purpuric skin lesions in one patient. All were diagnosed via skin biopsy (a purpuric lesion, hemangioma-like lesion and random normal skin, respectively) which revealed intravascular atypical B cells. Two patients developed hemophagocytic syndrome (HPS), aligning with the Asian variant of IVLBCL. One patient had hemangioma-like nodules and lymphadenopathy. These cases highlight the clinical heterogeneity of IVLBCL and emphasize the diagnostic value of skin biopsy in patients with features of HPS (unexplained fever, cytopenia, and elevated lactate dehydrogenase (LDH) or ferritin).</p>","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145022961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emerging Threats in Dermatophytosis: Antimicrobial Resistance in Trichophyton, with Emphasis on T. indotineae.","authors":"Vanessa H T Tey, Jiun Yit Pan","doi":"10.1093/ced/llaf414","DOIUrl":"https://doi.org/10.1093/ced/llaf414","url":null,"abstract":"<p><p>Antimicrobial-resistant Trichophyton infections have emerged as a significant global health concern. We reviewed the literature on their clinical manifestations, resistance mechanisms, and diagnostic and treatment challenges, focusing on Trichophyton indotineae (T. indotineae). Molecular tests for species identification and susceptibility testing are key to manage these infections effectively. There is an urgent need for further research and development to enhance our surveillance, diagnosis, and treatment of these emerging threats.</p>","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145022989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}